Kemadrin Tablets 5 Mg
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Kemadrin Tablets 5mg
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Procyclidine Hydrochloride BP 5 mg per tablet
Excipients with known effect: Lactose
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM Tablet
White, round, biconvex tablets, one face with a break-line and coded KT above the break-line and 05 below the break-line, with a score-line on the other face.
The tablet can be divided into equal doses.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Kemadrin is indicated for the treatment and symptomatic relief of all forms of Parkinson’s disease e.g. idiopathic (paralysis agitans), postencephalitic and arteriosclerotic disease.
Kemadrin is also indicated for the control of extrapyramidal symptoms induced by neuroleptic drugs including pseudo-parkinsonism, acute dystonic reactions and akathisia.
4.2 Posology and method of administration
The variation in optimum dosage from one patient to another should be taken into consideration by the physician.
Dosage in adults:
Parkinson’s disease:
Treatment is usually started at 2.5 mg procyclidine three times per day, increasing by
2.5 to 5 mg per day at intervals of two or three days until the optimum clinical response is achieved.
The usual maintenance dose to achieve optimal response is 15 to 30 mg procyclidine per day.
Addition of a fourth dose before retiring has been seen to be beneficial in some patients. Doses up to 60 mg procyclidine have been well tolerated, and at the discretion of the attending physician dosing to this level may be appropriate.
In general younger patients or those with postencephalitic parkinsonism may require higher doses for a therapeutic response than older patients and those with arteriosclerotic parkinsonism.
Kemadrin may be combined with levodopa or amantadine in patients who are inadequately controlled on a single agent.
Neuroleptic-induced extrapyramidal symptoms
Treatment is usually initiated at 2.5 mg procyclidine three times per day increasing by
2.5 mg daily until symptoms are relieved.
The effective maintenance dose is usually 10 to 30mg procyclidine per day. After a period of 3 to 4 months of therapy, Kemadrin should be withdrawn and the patient observed to see whether the neuroleptic-induced extra-pyramidal symptoms recur.
If this is the case Kemadrin should be reintroduced to avoid debilitating extrapyramidal symptoms. Cessation of treatment periodically is to be recommended even in patients who appear to require the drug for longer periods.
Paediatric population
The use of Kemadrin in this age group is not recommended.
Older people
Elderly patients may be more susceptible than younger adults to the anticholinergic effects of Kemadrin and a reduced dosage may be required (see section 4.4).
Method of administration
Pharmacokinetic studies have indicated that the mean plasma elimination half-life of Kemadrin is sufficient to allow twice daily administration orally, if more convenient.
Oral administration may be better tolerated if associated with a meal.
Tablets can be divided into equal doses.
4.3 Contraindications
Kemadrin is contra-indicated in individuals with known hypersensitivity to any component of the preparation, untreated urinary retention, closed angle glaucoma and gastro-intestinal obstruction.
4.4 Special warnings and precautions for use
As with all anticholinergics the benefit/risk ratio should be assessed when prescribing Kemadrin in patients with existing angle-closure (narrow angle) glaucoma or those considered to be predisposed to glaucoma. Cautious prescribing is also indicated in patients predisposed to obstructive disease of the gastro-intestinal tract and those with urinary symptoms associated with prostatic hypertrophy.
In a proportion of patients undergoing neuroleptic treatment, tardive dysknesias will occur. While anticholinergic agents do not cause this syndrome, when given in combination with neuroleptics they may exacerbate the symptoms of tardive dyskinesia or reduce the threshold at which these symptoms appear in predisposed patients. In such individuals subsequent adjustment of neuroleptic therapy or reduction in anticholinergic treatment should be considered.
Patients with mental disorders occasionally experience a precipitation of a psychotic episode when procyclidine is administered for the treatment of the extrapyramidal side effects of neuroleptics.
Elderly patients, especially those on high doses of anticholinergics may be more susceptible to the adverse events associated with such therapy (see section 4.8). Specifically, the elderly patient may be particularly vulnerable to Central Nervous System disturbances such as confusion, impairment of cognitive function and memory, disorientation and hallucinations. These effects are usually reversible on reduction or discontinuation of anticholinergic therapy.
There is no specific information available concerning the use of procyclidine hydrochloride in patients with impaired renal or hepatic function. However, since procyclidine is metabolised in the liver and excreted via the urine care should be exercised when administering procyclidine to patients with impairment of renal or hepatic function.
Kemadrin should not be withdrawn abruptly as rebound parkinsonian symptoms may occur.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Abuse
Kemadrin, along with other anticholinergic drugs, has the potential to be abused. Although the cases of abuse are rare, physicians should exercise caution in prescribing Kemadrin to patients with symptoms that may not be genuine.
4.5 Interaction with other medicinal products and other forms of interaction
Monoamine oxidase inhibitors or drugs with anticholinergic properties, such as amantadine, memantine, antihistamines, phenothiazines, tricyclic and related antidepressants, clozapine, disopyramide and nefopam may increase the anticholinergic action of procyclidine.
The use of drugs with cholinergic properties, such as tacrine, may reduce the therapeutic response to Kemadrin. Furthermore, drugs with anticholinergic properties may antagonise the effect of parasympathomimetic agents.
The concomitant use of procyclidine with some neuroleptics for the treatment of extrapyramidal symptoms has been associated with a reduction in neuroleptic plasma concentrations. However this reduction is unlikely to be associated with a significant reduction in clinical effect.
Drugs with anticholinergic properties may decrease salivation causing dry mouth and, in theory, may reduce the absorption and therefore the therapeutic effect of sublingual or buccal nitrate tablets.
Anticholinergics, including procyclidine, may reduce the efficacy of levodopa by increasing gastric emptying time, resulting in enhanced gastric degradation.
The effect of anticholinergics such as procyclidine may antagonise the gastrointestinal effects of cisapride, domperidone and metoclopramide.
Procyclidine may potentiate the vagolytic effects of quinidine.
Anticholinergics may reduce the absorption of ketoconazole.
Exposure to high environmental temperature and humidity in association with a phenothiazine/anticholinergic drug regimen has rarely resulted in hyperpyrexia.
Daily administration of paroxetine increases significantly the plasma levels of procyclidine. If anticholinergic effects are seen, the dose of procyclidine should be reduced.
4.6 Fertility, pregnancy and lactation
Pregnancy:
The safety of using Kemadrin during pregnancy has not been established. However, extensive clinical use has not given any evidence that it in any way compromises the normal course of pregnancy. Nevertheless, as with all drugs, use should be considered only when the expected clinical benefit of treatment for the mother outweighs any possible risk to the developing foetus.
Breastfeeding:
No information is available on the passage of procyclidine into human breast milk following administration of Kemadrin.
4.7 Effects on ability to drive and use machines
Adverse events of a neurological character such as blurred vision, dizziness, confusion and disorientation have been reported with procyclidine. Therefore, if affected, patients should be advised not to drive or operate machinery.
4.8 Undesirable effects
For this preparation there is no modern clinical documentation which can be used as support for determining the frequency of adverse reactions.
|
Psychiatric disorders |
Uncommon (>1/1000 and <1/100) |
Agitation, anxiety, nervousness, confusion, disorientation, hallucinations |
|
Rare (<1/1000) |
Psychotic disorder | |
|
Nervous system disorders |
Uncommon (>1/1000 and <1/100) |
Dizziness, memory impairment, impaired cognition |
|
Eye disorders |
Common (> 1/100) |
Blurred vision |
|
Gastrointestinal disorders |
Common (> 1/100) |
Dry mouth, constipation |
|
Uncommon (>1/1000 and <1/100) |
Nausea, vomiting, gingivitis | |
|
Skin and subcutaneous tissue disorder |
Uncommon (>1/1000 and <1/100) |
Rash |
|
Renal and urinary disorders |
Common (>1/100) |
Urinary retention |
The main undesirable effects are those to be expected from any anticholinergic agent - these are generally reversible on reducing the dosage.
With high doses of procyclidine dizziness, mental confusion, impaired cognition and memory, disorientation, anxiety, agitation and hallucinations may occur.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
4.9 Overdose
Symptoms and signs
Symptoms of overdosage include stimulant effects such as agitation, restlessness and confusion with severe sleeplessness lasting up to 24 hours or more. Visual and auditory hallucinations have been reported. Most subjects are euphoric but the occasional patient may be anxious and aggressive. The pupils are widely dilated and unreactive to light. In recorded cases, the disorientation has lasted 1 to 4 days and ended in a recuperative sleep. Signs of CNS depression including somnolence, reduced consciousness, and occasionally coma have been reported usually following very large overdoses.
Tachycardia has also been reported in association with cases of Kemadrin overdose. Treatment
If procyclidine has been ingested within the previous hour or two (or possibly longer in view of its likely effects on gastric motility) then activated charcoal should be used to reduce absorption. Gastric lavage should only be considered if clinically appropriate. Other active measures such as the use of cholinergic agents or haemodialysis are extremely unlikely to be of clinical value although if convulsions occur they should be controlled by injections of diazepam.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Anticholinergic group, ATC code: N04A A04.
Procyclidine is a synthetic anticholinergic agent which blocks the excitatory effects of acetylcholine at the muscarinic receptor.
Idiopathic Parkinson’s disease is thought to result from degeneration of neurones in the substantia nigra whose axons project and inhibit cells in the corpus striatum. Blockade by neuroleptic drugs of the dopamine released by these terminals produces a similar clinical picture. The cell bodies in the corpus striatum also receive cholinergic innervation which is excitatory.
Relief of the Parkinsonian syndrome can be achieved, either by potentiation of the dopaminergic system or blockade of the cholinergic input by anticholinergics. It is by a central action of this latter type by which procyclidine exerts its effect.
Procyclidine is particularly effective in the alleviation of rigidity. Tremor, akinesia, speech and writing difficulties, gait, sialorrhoea and drooling, sweating, oculogyric crises and depressed mood are also beneficially influenced.
5.2 Pharmacokinetic properties
Procyclidine is adequately absorbed from the gastro-intestinal tract with a bioavailability of 75% and disappears rapidly from the tissues. The relatively low clearance of 68 ml/min represents a predominantly metabolic change with a small first pass effect. The mean plasma elimination half-life after both oral and intravenous administration is approximately 12hours.
No detailed information is available on the metabolic fate of procyclidine but very little of the parent compound is excreted in the urine unchanged. When given orally about one fifth of the dose is known to be metabolised in the liver, principally by cytochrome P450 and then conjugated with glucuronic acid. This conjugate has been detected in the urine.
5.3 Preclinical safety data
Fertility
A three generation study in rats dosed at 40 mg/kg/day via the diet before and during pregnancy showed only that the number of viable pups was slightly decreased from the second mating. No other parameters were affected.
Teratogenicity
No teratogenic effects were seen in rats dosed subcutaneously with 10, 30 or 100 mg/kg/day on days 8 to 16 of pregnancy. Maternal bodyweight gain was reduced at doses of 30 or 100 mg/kg/day, and a 10% reduction in foetal weight was seen at 100 mg/kg/day
Carcinogenicity, mutagenicity
Procyclidine was not genotoxic in in vitro bacterial mutation or mouse lymphoma assays.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Lactose
Sodium Starch Glycollate Povidone
Magnesium Stearate
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
5 years.
6.4 Special precautions for storage
Do not store above 25 °C.
6.5 Nature and contents of container
Amber glass bottles with low density polyethylene snap fit closures. Pack sizes50,100.
Polypropylene containers with polyethylene snap-fit lids. Pack size500. Round enamelled tins with lever lids. Pack size 5,000.
6.6 Special precautions for disposal
See section 4.2 posology and method of administration.
7 MARKETING AUTHORISATION HOLDER
Aspen Pharma Trading Limited 3016 Lake Drive Citywest Business Campus Dublin 24 Ireland
8 MARKETING AUTHORISATION NUMBER(S)
PL 39699/0046
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
19/09/2006
10 DATE OF REVISION OF THE TEXT
21/02/2016